Table 2 Details of first-line chemotherapy in patients with LCNEC of NLR < 5 or NLR ≥ 5 (n = 67).

From: Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

 

NLR < 5

n = 47

NLR ≥ 5

n = 16

p*

Regimen of initial chemotherapy, n (%)

 Platinum + CPT

29 (61.7)

8 (50)

 

 Platinum + ETP

10 (21.3)

6 (37.5)

 

 Platinum + PTX

3 (6.4)

0 (0.0)

 

 AMR

3 (6.4)

2 (12.5)

 

 Other

2 (4.2)

0 (0.0)

 

Cycles of chemotherapy, median (range)

2.0 (1–8)

1.0 (1–5)

 

Response to initial chemotherapy, n (%)

 Partial response

23 (48.9)

4 (28.6)

0.23

 Stable disease

11 (23.4)

5 (35.7)

 

 Progressive disease

13 (27.7)

5 (35.7)

 

 Not evaluated

0

2

 
  1. NLR neutrophil-to-lymphocyte ratio, CPT irinotecan, ETP etoposide, PTX paclitaxel, AMR amrubicin.
  2. *p values were analysed using the χ² test.
Back to article page